Skip Navigation


European Heart Journal Advance Access originally published online on August 25, 2005
European Heart Journal 2005 26(21):2344-2345; doi:10.1093/eurheartj/ehi466
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/21/2344-a    most recent
ehi466v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Farnier, M.
Right arrow Articles by Gumbiner, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Farnier, M.
Right arrow Articles by Gumbiner, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Ezetimibe coadministered with fenofibrate: some safety questions: reply

Michel Farnier

Point Medical
Dijon, France
E-mail address: mfarnier@ipac.fr

Michael J. Davies, Yale B. Mitchel and Barry Gumbiner

Merck Research Laboratory
RY34-A216
Rahway, NJ 07065
USA

The first 10% of the full text of this article appears below.

We thank Dr Borja for interest in our work1 and this letter allows us to expand on the criteria related to creatine kinase (CK) elevations used in our study. First, it is important to state that there were no measured CK elevations more than 10 times upper limit of normal . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?